Previous studies have reported the oncogenic role of TMED2 in some cancers, including hepatocellular carcinoma and prostate cancer.17 For example, Zheng, et al.25 (2016) reported the significant upregulation of TMED2 in hepatocellular carcinoma, correlating it with poor clinical outcomes, whereas Vainio, et al. (2012) identified TMED3 as a potential drug target for prostate cancer.24 This evidence concerns the gene TMED2 and hepatocellular carcinoma.